查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004660

異味止汗劑市場：依產品類型、給藥途徑、最終用戶和通路分類－2026-2032年全球市場預測

Bromhidrosis Disease Treatment Market by Product Type, Mode Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，體臭治療市場價值將達到 5.3667 億美元，到 2026 年將成長至 5.818 億美元，到 2032 年將達到 10.2693 億美元，年複合成長率為 9.71%。

主要市場統計數據
基準年 2025 5.3667億美元
預計年份：2026年 5.818億美元
預測年份 2032 1,026,930,000 美元
複合年成長率 (%) 9.71%

本文概述了現代體臭診斷和治療方法的臨床複雜性和跨學科需求。

口臭是一種複雜的臨床疾病，涉及皮膚科、外科和個人衛生用品，需要多學科協作治療。患者面臨心理和生理上的雙重負擔，需要多種治療方案，從局部止汗劑到侵入性手術。因此，臨床醫生和商業團隊在製定治療方案和產品系列時，必須權衡療效、安全性、患者意願和治療成本之間的平衡。

治療方法、管理系統和護理模式的創新如何重新定義汗臭症的治療範式和治療途徑。

體臭治療領域正經歷一場變革，主要得益於治療方法、給藥系統和照護模式的創新。新型外用製劑和先進的止汗技術提高了患者的耐受性和依從性，而標靶注射則為臨床醫生提供了一種微創治療方案，同時滿足了患者的美容需求。同時，設備工程技術的進步也提升了離子導入設備的便攜性和易用性，進而擴大了居家治療的覆蓋範圍。

本研究評估了近期影響醫療進口的關稅調整如何重塑口腔異味症治療的供應鏈、籌資策略和治療方案。

影響醫療用品進口的關稅政策變化可能會對整個煙味治療生態系統產生連鎖反應，進而影響供應鏈決策和供應商選擇。進口藥品、注射劑和專用手術器械關稅的提高可能會推高整體成本，並促使企業在地採購和策略性庫存管理。因此，採購團隊可能需要重新審視與供應商的合約以及物流策略，以確保治療的連續性。

將產品形式、給藥途徑、分銷管道和最終用戶狀態與治療引入趨勢聯繫起來的實用細分情報。

細分市場分析揭示了每種產品類型、給藥途徑、通路和最終用戶的不同商業性和臨床路徑，每種路徑都有其獨特的市場推廣趨勢。就產品類型而言，通訊協定。離子導入設備有攜帶式和固定式兩種設計，這會影響患者的依從性和診所的容量。手術選擇包括刮除術、局部切除術和內視鏡胸切除術，每種手術都有其獨特的風險效益比。

區域趨勢和以當地為中心的策略：本節闡明了臨床實踐、法律規範和分銷模式在全球主要區域之間的差異。

區域分析揭示了美洲、歐洲、中東、非洲和亞太地區在商業性趨勢和臨床實踐模式上的顯著差異，凸顯了各地區在監管、支付方和服務提供方面的顯著差異。在美洲，私立專科診所和零售分銷網路在提供非侵入性治療方面發揮著至關重要的作用，注射劑和醫療設備類解決方案在門診環境中也廣受歡迎。同時，醫院診療路徑在外科手術和複雜護理的協調方面仍然發揮著重要作用。

汗臭治療生態系中主要製藥、醫療設備和臨床服務提供者的競爭與合作要求。

治療體臭的競爭日益激烈，這源自於製藥公司、醫療設備開發商、外科服務提供者和分銷合作夥伴之間的互動。開發肉毒桿菌素製劑的製藥公司透過臨床數據、穩定性分析和醫生培訓計畫來凸顯自身優勢。醫療設備製造商則在人體工學、便攜性和連接性方面展開競爭，這些優勢使得居家使用和遠端用藥依從性監測成為可能。同時，外科中心和專科診所正透過其在手術操作和治療結果報告方面的專業知識來提升自身的價值提案。

高階主管已確定了可操作的策略重點，以加強臨床和分銷管道中證據、供應彈性和市場對市場策略的一致性。

產業領導者應優先考慮整合臨床證據、增強分銷韌性以及與目標相關人員積極互動的整合策略，以最大限度地發揮不斷變化的治療偏好帶來的益處。首先，投資進行療效比較研究和上市後監測，以展現產品在真實世界中的療效並增強臨床醫生的信心。其次，透過採購管道多元化、建立本地夥伴關係以及完善庫存管理通訊協定，加強供應鏈韌性，以減輕進口中斷的影響。第三，透過使製劑特性和醫療設備功能與給藥環境和患者便利性相匹配，最佳化產品系列。

調查方法結合了對臨床醫生的訪談、供應鏈檢驗和嚴格的二次分析，提供了可操作的產業見解。

本研究透過整合對臨床醫生、採購經理和分銷主管的訪談，以及對同行評審的臨床文獻、監管申報文件和供應商文件的二次分析，建構了全面的證據基礎。為檢驗準確反映治療方案和治療偏好方面的細微差異，我們與皮膚科醫生、外科醫生及相關醫療保健專業人員進行了結構化討論，從而驗證了臨床見解。供應鏈和分銷趨勢是基於對物流經理和通路合作夥伴的訪談，反映了現代採購和履約的實際情況。

策略意義的整合，重點闡述了證據、供應韌性和協作如何相互交織，以推進煙味治療。

總之，在治療方法創新、醫療設備改善和醫療服務模式變革的推動下，體臭症的治療正經歷顯著的變革。這些變革為改善患者預後、擴大居家和門診治療的覆蓋範圍以及最佳化臨床路徑以提高效率提供了絕佳機會。同時，政策變革和供應鏈中斷也凸顯了積極規劃和彈性商業策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：引起異味的汗症治療市場：依產品類型分類

  • 止汗劑
    • 奶油
    • 滾珠式
    • 噴
    • 戳
  • 肉毒桿菌毒素
    • 阿伏肉毒素A
    • 肉毒桿菌A
    • 肉毒桿菌A
  • 離子泳
    • 攜帶式
    • 固定設備
  • 外科手術
    • 刮宮術
    • 內視鏡胸切除術
    • 局部切除

第9章：以給藥方式治療體臭的市場

  • 注射藥物
    • 皮內注射
    • 皮下
  • 外用
    • 奶油
    • 凝膠
    • 滾珠式
    • 噴

第10章：與異味相關的汗症治療市場：依最終用戶分類

  • 皮膚科診所
    • 連鎖診所
    • 私人診所
  • 居家照護
  • 醫院
    • 私立醫院
    • 公立醫院

第11章：異味性多汗症治療市場：依分銷管道分類

  • 電子商務
  • 醫院藥房
  • 零售藥房

第12章 汗臭治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：與異味相關的汗症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：各國異味性汗症治療市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國滲透性痔瘡治療市場

第16章 中國臭汗症治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Allergan plc
  • Almirall, SA
  • Bausch Health Companies Inc.
  • Biovencer Healthcare Pvt. Ltd.
  • Celgene Corporation
  • Cutera, Inc.
  • Galderma SA
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals Plc
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Journey Medical Corporation
  • Leo Pharma A/S
  • Medytox, Inc.
  • Merck & Co., Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Miramar Labs, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.
Product Code: MRR-742BD517C23C

The Bromhidrosis Disease Treatment Market was valued at USD 536.67 million in 2025 and is projected to grow to USD 581.80 million in 2026, with a CAGR of 9.71%, reaching USD 1,026.93 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 536.67 million
Estimated Year [2026] USD 581.80 million
Forecast Year [2032] USD 1,026.93 million
CAGR (%) 9.71%

Framing the clinical complexity and multidisciplinary imperatives that define contemporary approaches to bromhidrosis diagnosis and treatment

Bromhidrosis remains a complex clinical condition that intersects dermatology, surgical practice, and consumer hygiene products, demanding multidisciplinary attention. Patients confront both psychosocial and physiological burdens, prompting diverse treatment choices from topical antiperspirants to invasive surgical interventions. Clinicians and commercial teams must therefore balance efficacy, safety, patient preference, and cost of care when developing care pathways and product portfolios.

Over recent years, innovation across pharmaceutical formulations, minimally invasive procedures, and consumer-facing antiperspirant technologies has reshaped therapeutic options. Consequently, payers and providers are reassessing pathways to improve outcomes while controlling resource utilization. As a result, stakeholders face new imperatives around evidence generation, physician education, and supply chain resilience.

Given this context, the introduction synthesizes clinical drivers, evolving patient expectations, and the competitive landscape to frame subsequent analysis. It also establishes the need for integrated strategies that bridge clinical efficacy with accessible care delivery. Moving forward, the report highlights priority areas for investment and collaboration across manufacturing, clinical research, and distribution to optimize patient-centric outcomes.

How innovation in therapeutics, delivery systems, and care models is redefining treatment paradigms and access pathways for bromhidrosis care

The bromhidrosis landscape has experienced transformative shifts driven by innovation in therapeutics, delivery systems, and care delivery models. Novel topical formulations and refined antiperspirant technologies have enhanced tolerability and patient adherence, while targeted injectable therapies have provided clinicians with minimally invasive alternatives that align with aesthetic expectations. At the same time, advances in device engineering have improved the portability and usability of iontophoresis units, expanding access for home-based management.

Simultaneously, surgical techniques have evolved toward less invasive approaches that reduce recovery time and complication rates, prompting a reclassification of procedural indications and referral patterns. These clinical shifts are accompanied by changes in distribution behavior: e-commerce channels increasingly deliver consumer-centric products, specialty clinics expand service offerings, and hospital-based pathways adapt to outpatient procedural trends. Consequently, product developers and service providers must reconcile clinical evidence generation with user experience and distribution strategies.

Taken together, these developments create both opportunities and challenges. Stakeholders who synchronize clinical innovation with clear value communication and robust supply channels will be best positioned to capitalize on changing treatment preferences and to support patient-centered care.

Evaluating how recent tariff adjustments affecting medical imports can reshape supply chains, procurement strategies, and treatment availability in bromhidrosis care

Tariff policy modifications affecting imports and medical goods can ripple through the bromhidrosis treatment ecosystem, influencing supply chain decisions and supplier selection. Increased duties on imported pharmaceuticals, injectable formulations, and specialized surgical instruments can raise landed costs and create incentives for local sourcing or strategic inventory buffering. As a result, procurement teams reassess supplier contracts and logistical strategies to preserve continuity of care.

Moreover, tariffs can alter competitive dynamics among manufacturers and distributors. Companies dependent on cross-border supply of active pharmaceutical ingredients or device components may accelerate vertical integration, diversify supplier bases, or renegotiate pricing structures. These adjustments influence product availability, lead times for devices such as iontophoresis units, and the cost profile for botulinum toxin preparations used in treatment regimens.

Clinicians and health systems may respond by revisiting treatment algorithms and protocol selection, prioritizing options with stable supply chains and lower procurement volatility. For policymakers and industry leaders, the cumulative impact underscores the importance of scenario planning and supplier risk assessment to maintain patient access and to prevent downstream disruption in care delivery.

Actionable segmentation intelligence linking product formats, administration routes, distribution channels, and end-user contexts to treatment adoption dynamics

Segmentation insights reveal distinct commercial and clinical pathways across product types, administration modes, distribution routes, and end users, each of which carries specific adoption dynamics. Across product type, antiperspirants span cream, roll-on, spray, and stick formats that emphasize consumer accessibility and over-the-counter convenience; botulinum toxin options include variants such as abobotulinumtoxinA, incobotulinumtoxinA, and onabotulinumtoxinA that differ by clinical handling and dosing protocols; iontophoresis devices appear in portable and stationary designs that influence patient adherence and clinic throughput; surgical choices range from curettage and local excision to endoscopic thoracic sympathectomy, with each technique presenting unique risk-benefit profiles.

Considering mode of administration, injectable therapies subdivide into intradermal and subcutaneous approaches that affect training requirements and procedure settings, while topical options such as creams, gels, roll-ons, and sprays vary in formulation complexity and patient usage patterns. Distribution channels include e-commerce platforms, hospital pharmacies, retail pharmacies, and specialty clinics, each offering different margins, compliance supports, and data capture opportunities. End users encompass dermatology clinics-both chain and independent practices-home care settings, and hospital environments including private and public institutions, with each end user exhibiting divergent purchasing cycles, reimbursement contexts, and clinical preferences.

Consequently, an integrated product and commercial strategy must reconcile formulation design, administration logistics, channel selection, and end-user engagement to maximize clinical uptake and long-term adherence.

Regional dynamics and localized strategies revealing how clinical practice, regulatory frameworks, and distribution patterns vary across major global territories

Regional insights underscore that commercial dynamics and clinical practice patterns vary substantially across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct regulatory, payer, and service delivery characteristics. In the Americas, private specialty clinics and retail distribution networks play a prominent role in delivering noninvasive treatments, and there is high receptivity to injectable and device-based solutions within outpatient settings. Conversely, hospital-based pathways remain influential for surgical interventions and for complex care coordination.

In Europe, the Middle East, and Africa region, regulatory heterogeneity and divergent reimbursement frameworks shape adoption, with some markets demonstrating rapid uptake of minimally invasive therapies while others emphasize conservative, guideline-driven approaches. The Asia-Pacific region exhibits a mix of centralized public hospital systems and rapidly expanding private specialty clinics; local manufacturing capabilities in some countries influence device availability and price dynamics, and cultural attitudes toward treatment modalities can significantly affect patient demand.

Taken together, regional differentiation necessitates tailored commercialization and regulatory strategies that account for local clinical practice, distribution infrastructure, and payer engagement. Companies that align product positioning and evidence generation to these regional nuances will better navigate adoption barriers and accelerate clinician and patient acceptance.

Competitive and collaborative imperatives that distinguish leading pharmaceutical, device, and clinical service players in the bromhidrosis treatment ecosystem

Competitive intensity in bromhidrosis treatment arises from the interplay of pharmaceutical manufacturers, device developers, surgical service providers, and distribution partners. Pharmaceutical firms that develop botulinum toxin formulations differentiate through clinical data, stability profiles, and physician training programs. Device manufacturers compete on ergonomics, portability, and connectivity features that enable home use and remote adherence monitoring. Meanwhile, surgical centers and specialty clinics enhance their value proposition through procedural expertise and outcome reporting.

Partnerships between manufacturers and distribution channels are increasingly strategic, as e-commerce platforms and specialty clinics seek to bundle product access with patient education and follow-up services. In addition, companies investing in clinician training and digital support tools tend to secure deeper clinical engagement and more consistent utilization. Regulatory compliance, supply chain transparency, and demonstrated real-world outcomes represent decisive factors in vendor selection by large hospitals and integrated care networks.

Overall, success in this space favors organizations that combine robust clinical evidence with seamless delivery models and responsive commercial support. Strategic collaborations across the value chain, backed by transparent quality systems and clinician-focused initiatives, will continue to shape competitive advantage and long-term sustainability.

Practical strategic priorities for executives to strengthen evidence, supply resilience, and go-to-market alignment across clinical and distribution channels

Industry leaders should prioritize integrated strategies that combine clinical evidence generation, distribution resilience, and targeted stakeholder engagement to capitalize on evolving treatment preferences. First, invest in comparative effectiveness studies and post-market surveillance to substantiate real-world benefits and to support clinician confidence. Second, strengthen supply chain resilience through diversified sourcing, local partnerships, and inventory management protocols that attenuate the impact of import-related disruptions. Third, optimize product portfolios by aligning formulation attributes and device features with administration settings and patient convenience.

Additionally, develop channel-specific go-to-market approaches: enhance e-commerce offerings with patient education and adherence support; equip specialty clinics with training modules and outcome-tracking tools; and establish hospital partnerships that facilitate procedural integration. Simultaneously, engage payers and guideline-setting bodies to articulate value propositions rooted in clinical outcomes and care pathway efficiencies. Finally, adopt digital engagement and telehealth-enabled follow-up to improve continuity of care and to collect actionable real-world data.

By executing these priorities, organizations can reduce adoption friction, improve patient outcomes, and create defensible positioning in a marketplace characterized by clinical nuance and distribution complexity.

Methodological approach combining clinician interviews, supply chain validation, and rigorous secondary analysis to deliver actionable industry intelligence

This research synthesizes primary interviews with clinicians, procurement leaders, and distribution executives alongside secondary analysis of peer-reviewed clinical literature, regulatory filings, and supplier documentation to create a comprehensive evidence base. Clinical insights were validated through structured discussions with dermatologists, surgeons, and allied health practitioners to ensure that procedural nuances and treatment preferences were accurately represented. Supply chain and distribution dynamics were informed by interviews with logistics managers and channel partners to reflect contemporary sourcing and fulfillment realities.

Analytical methods include qualitative thematic analysis to identify adoption drivers and barriers, triangulation across data sources to validate assumptions, and scenario planning to explore supply chain contingencies and policy impacts. Wherever appropriate, clinical claims and device characteristics were cross-referenced with regulatory approvals and published outcomes to maintain factual accuracy. Throughout, the research prioritized transparency in methodology and source attribution to support reproducibility and to enable stakeholders to apply findings to their strategic planning.

These combined methods produce an actionable and defensible synthesis of clinical, commercial, and operational considerations relevant to bromhidrosis treatment stakeholders.

Synthesis of strategic implications highlighting where evidence, supply resilience, and collaboration converge to advance bromhidrosis care

In conclusion, bromhidrosis treatment is undergoing a period of substantive evolution driven by therapeutic innovation, device improvements, and shifting care delivery models. These changes offer notable opportunities to improve patient outcomes, to expand access through home-based and outpatient options, and to refine clinical pathways for greater efficiency. At the same time, policy shifts and supply chain disruptions underscore the need for proactive planning and adaptive commercial strategies.

Looking ahead, organizations that integrate robust clinical evidence with resilient sourcing, tailored distribution approaches, and targeted stakeholder engagement will lead adoption and deliver superior patient experiences. Cross-sector collaboration among manufacturers, clinicians, and distributors will be essential to translate innovation into sustained clinical practice. In short, the path forward requires coordinated investment in evidence, infrastructure, and clinician support to fully realize the clinical and commercial potential of emerging treatments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bromhidrosis Disease Treatment Market, by Product Type

  • 8.1. Antiperspirants
    • 8.1.1. Cream
    • 8.1.2. Roll-On
    • 8.1.3. Spray
    • 8.1.4. Stick
  • 8.2. Botulinum Toxin
    • 8.2.1. AbobotulinumtoxinA
    • 8.2.2. IncobotulinumtoxinA
    • 8.2.3. OnabotulinumtoxinA
  • 8.3. Iontophoresis
    • 8.3.1. Portable Devices
    • 8.3.2. Stationary Devices
  • 8.4. Surgery
    • 8.4.1. Curettage
    • 8.4.2. Endoscopic Thoracic Sympathectomy
    • 8.4.3. Local Excision

9. Bromhidrosis Disease Treatment Market, by Mode Of Administration

  • 9.1. Injectable
    • 9.1.1. Intradermal
    • 9.1.2. Subcutaneous
  • 9.2. Topical
    • 9.2.1. Cream
    • 9.2.2. Gel
    • 9.2.3. Roll-On
    • 9.2.4. Spray

10. Bromhidrosis Disease Treatment Market, by End User

  • 10.1. Dermatology Clinics
    • 10.1.1. Chain Clinics
    • 10.1.2. Independent Clinics
  • 10.2. Home Care
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals

11. Bromhidrosis Disease Treatment Market, by Distribution Channel

  • 11.1. E-Commerce
  • 11.2. Hospital Pharmacy
  • 11.3. Retail Pharmacy

12. Bromhidrosis Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bromhidrosis Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bromhidrosis Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bromhidrosis Disease Treatment Market

16. China Bromhidrosis Disease Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Allergan plc
  • 17.7. Almirall, S.A.
  • 17.8. Bausch Health Companies Inc.
  • 17.9. Biovencer Healthcare Pvt. Ltd.
  • 17.10. Celgene Corporation
  • 17.11. Cutera, Inc.
  • 17.12. Galderma SA
  • 17.13. GlaxoSmithKline plc
  • 17.14. Hikma Pharmaceuticals Plc
  • 17.15. Ipsen Pharma
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Journey Medical Corporation
  • 17.18. Leo Pharma A/S
  • 17.19. Medytox, Inc.
  • 17.20. Merck & Co., Inc.
  • 17.21. Merz Pharma GmbH & Co. KGaA
  • 17.22. Miramar Labs, Inc.
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Regeneron Pharmaceuticals, Inc.
  • 17.26. Valeant Pharmaceuticals International, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ROLL-ON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ROLL-ON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ROLL-ON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY STICK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY STICK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY STICK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ABOBOTULINUMTOXINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ABOBOTULINUMTOXINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ABOBOTULINUMTOXINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INCOBOTULINUMTOXINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INCOBOTULINUMTOXINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INCOBOTULINUMTOXINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ONABOTULINUMTOXINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ONABOTULINUMTOXINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ONABOTULINUMTOXINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PORTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PORTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PORTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY STATIONARY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY STATIONARY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY STATIONARY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CURETTAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CURETTAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CURETTAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ENDOSCOPIC THORACIC SYMPATHECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ENDOSCOPIC THORACIC SYMPATHECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ENDOSCOPIC THORACIC SYMPATHECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY LOCAL EXCISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY LOCAL EXCISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY LOCAL EXCISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ROLL-ON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ROLL-ON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ROLL-ON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CHAIN CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CHAIN CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY CHAIN CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 278. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 280. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY ANTIPERSPIRANTS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 291. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY IONTOPHORESIS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 295. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 296. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES BROMHIDROSIS DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES BR